drugset / Trial / NCT06947291

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

NCT06947291

Phase 2 Recruiting 350 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The trial consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (proof-of-concept study). Among them, Stage 2 adopts a randomized, controlled, open-label, and multicenter design.

Timeline

Start
2025-06-04
Primary completion
2027-04-30
Completion
2027-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule Intravenous
Subject Gumarontinib Small molecule

Indications